Cargando…
Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
Inhibitors of cyclo-oxogenase (COX) are widely used anti-inflammatory drugs. In recent years concerns have arisen about the cardiovascular safety of these drugs, initially because of reported associations between therapy with the COX-2 selective inhibitor rofecoxib and myocardial infarction. However...
Autor principal: | Howes, Laurence Guy |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376081/ https://www.ncbi.nlm.nih.gov/pubmed/18473007 |
Ejemplares similares
-
Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
por: Borer, Jeffrey S, et al.
Publicado: (2005) -
Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs
por: Scheiman, James M, et al.
Publicado: (2005) -
Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
por: Walker, Chris
Publicado: (2018) -
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
por: Rostom, Alaa, et al.
Publicado: (2009) -
Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib
por: Chugh, Shikha, et al.
Publicado: (2013)